THIRD PARTY STUDIES Clause Samples

The "Third Party Studies" clause governs the use, disclosure, or reliance on studies, reports, or analyses conducted by independent entities not directly involved in the contract. Typically, this clause outlines the conditions under which such third-party findings may be referenced, shared, or used as evidence in decision-making or dispute resolution between the contracting parties. For example, it may specify that only studies meeting certain standards or conducted by accredited organizations are acceptable. The core function of this clause is to ensure that any external information influencing the agreement is credible, relevant, and agreed upon by both parties, thereby reducing disputes over the validity of outside data.
THIRD PARTY STUDIES. Attached hereto as SCHEDULE 19 is a true, accurate and complete list of Engineering and Inspection Materials (as herein defined) to the best of Sellers' Knowledge in the possession of Sellers. For purposes of this Agreement, Engineering and Inspection Materials shall mean: (i) all Architectural/Engineering Working Drawings and Specifications for the Property including, but not limited to all "as built" drawings; (ii) any engineering plans and studies, including structural studies of the Property in the possession of Sellers; (iii) all site plans; (iv) any soil, substrata studies, or landscape plans in the possession of Sellers; (v) all floor plans; (vi) any appraisals of the Property commissioned by Sellers; (vii) the most recent inspection and certification reports made by any insurance carrier, codes or building department, fire marshal, OSHA or any state licensing authority in the possession of Sellers; or, (vii) any Environmental reports. With the delivery of this Agreement, Sellers has provided to Buyer an accurate and complete copy of each item set forth on SCHEDULE 19. Sellers make no representation or warranty as to the facts, circumstances or professional judgments set forth in such Third Party Studies.
View SourceView Similar (3)
THIRD PARTY STUDIES. Attached hereto as SCHEDULE 8.1.19 is, to Seller's best knowledge, a true, accurate and complete list of Engineering and Inspection Materials (as herein defined). For
View Source
THIRD PARTY STUDIES. Attached hereto as SCHEDULE 8.1.19 is, to Seller's best knowledge, a true, accurate and complete list of Engineering and Inspection Materials (as herein defined). For purposes of this Agreement, "Engineering and Inspection Materials" shall mean (i) all Architectural/Engineering Working Drawings and Specifications for the Property including, but not limited to all "as built" drawings in Seller's possession; (ii) any engineering plans and studies, including structural studies of the Property in the possession of Seller; (iii) all site plans in Seller's possession; (iv) any soil, substrata studies, or landscape plans in the possession of Seller; (v) all floor plans in Seller's possession; (vi) any appraisals of the Property commissioned by Seller and in Seller's possession; (vii) the most recent inspection and certification reports made by any insurance carrier, codes or building department, fire marshal, OSHA or any state licensing authority in the possession of Seller or (vii) any Environmental Reports in Seller's possession. With the delivery of this Agreement, Seller has provided to Buyer an accurate and complete copy of each item set forth on SCHEDULE 8.1.
View Source

Related to THIRD PARTY STUDIES

  • Clinical Studies The animal and other preclinical studies and clinical trials conducted by the Company or on behalf of the Company were, and, if still pending are, to the Company’s knowledge, being conducted in all material respects in compliance with all Applicable Laws and in accordance with experimental protocols, procedures and controls generally used by qualified experts in the preclinical study and clinical trials of new drugs and biologics as applied to comparable products to those being developed by the Company; the descriptions of the results of such preclinical studies and clinical trials contained in the Registration Statement and the Prospectus are accurate and complete in all material respects, and, except as set forth in the Registration Statement and the Prospectus, the Company has no knowledge of any other clinical trials or preclinical studies, the results of which reasonably call into question the clinical trial or preclinical study results described or referred to in the Registration Statement and the Prospectus when viewed in the context in which such results are described; and the Company has not received any written notices or correspondence from the FDA, the EMA, or any other domestic or foreign governmental agency requiring the termination, suspension or modification of any preclinical studies or clinical trials conducted by or on behalf of the Company that are described in the Registration Statement and the Prospectus or the results of which are referred to in the Registration Statement and the Prospectus.

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Development Activities The Development activities referred to in item “b” of paragraph 3.1 include: studies and projects of implementation of the Production facilities; drilling and completion of the Producing and injection ▇▇▇▇▇; and installation of equipment and vessels for extraction, collection, Treatment, storage, and transfer of Oil and Gas. The installation referred to in item “c” includes, but is not limited to, offshore platforms, pipelines, Oil and Gas Treatment plants, equipment and facilities for measurement of the inspected Production, wellhead equipment, production pipes, flow lines, tanks, and other facilities exclusively intended for extraction, as well as oil and gas pipelines for Production Outflow and their respective compressor and pumping stations.

  • Collaboration activities 4.1 The Collaboration Suppliers will perform the Collaboration Activities and all other obligations of this Agreement in accordance with the Detailed Collaboration Plan. 4.2 The Collaboration Suppliers will provide all additional cooperation and assistance as is reasonably required by the Buyer to ensure the continuous delivery of the services under the Call-Off Contract. 4.3 The Collaboration Suppliers will ensure that their respective subcontractors provide all cooperation and assistance as set out in the Detailed Collaboration Plan.

  • Development and Commercialization Subject to Sections 4.6 and 4.7, Fibrocell shall be solely responsible for the development and Commercialization of Fibrocell Products and Improved Products. Fibrocell shall be responsible for all costs incurred in connection with the Fibroblast Program except that Intrexon shall be responsible for the following: (a) costs of establishing manufacturing capabilities and facilities in connection with Intrexon’s manufacturing obligation under Section 4.6 (provided, however, that Intrexon may include an allocable portion of such costs, through depreciation and amortization, when calculating the Fully Loaded Cost of manufacturing a Fibrocell Product, to the extent such allocation, depreciation, and amortization is permitted by US GAAP, it being recognized that the majority of non-facilities scale-up costs cannot be capitalized and amortized under US GAAP); (b) costs of basic research with respect to the Intrexon Channel Technology and Intrexon Materials (i.e., platform improvements) but, for clarity, excluding research described in Section 4.7 or research requested by the JSC for the development of a Fibrocell Product or an Improved Product (which research costs shall be reimbursed by Fibrocell); (c) [*****]; and (d) costs of filing, prosecution and maintenance of Intrexon Patents. The costs encompassed within subsection (a) above shall include the scale-up of Intrexon Materials and related active pharmaceutical ingredients for clinical trials and Commercialization of Fibrocell Products undertaken pursuant to Section 4.6, which shall be at Intrexon’s cost whether it elects to conduct such efforts internally or through Third Party contractors retained by either Intrexon or Fibrocell (with Intrexon’s consent).